Ascentage Pharma Group International
AAPG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023311
No open-market purchases or sales by Ascentage Pharma Group International insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $263.5K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Ascentage Pharma Group International changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 14 | 1 | 12 | −1 |
| Shares | 94.1K | 17.9K | 47.8K | −28.4K (−37.3%) |
| Value | $3.69M | $700.0K | $1.25M | −$1.73M (−58.0%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Ascentage Pharma Group International at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 16,726 | $438.9K | 0.00% |
| Royal Bank of Canada | 6 | $0 | 0.00% |
Sold out (3)
Institutions that held Ascentage Pharma Group International at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| NEOS Investment Management LLC | 10,385 | $412.2K |
| Tema ETFs LLC | 10,385 | $405.4K |
| Abc Arbitrage SA | 5,230 | $204.2K |
Not filed for Q4 2025 yet (1)
Institutions that held Ascentage Pharma Group International at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Point72 (DIFC) Ltd | 17,930 | $700.0K |